Evidence map›Paper›PMID 29284412›Full record

ArticleBMC gastroenterology2017

CCL4 is the only predictor for non-responder in GT-1 CHC patients with favorable IL28B genotype when treated with PegIFN/RBV.

Chia-Chen Lin, Shih-Huan Su, Wen-Juei Jeng, Chien-Hao Huang, Wei Teng, Wei-Ting Chen, Yi-Cheng Chen, Chun-Yen Lin, I-Shyan Sheen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC gastroenterology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Chia-Chen LinSchool of Medicine, College of Medicine, Chang-Gung University, 5, Fu-Xin street, Quain San, TaoYuan, 330, Taiwan.
Shih-Huan SuSchool of Medicine, College of Medicine, Chang-Gung University, 5, Fu-Xin street, Quain San, TaoYuan, 330, Taiwan.
Wen-Juei JengDivision of Hepatology, Department of HepatoGastroenterology, Chang-Gung Memorial Hospital, Linkou Medical Center, TaoYuan, Taiwan.
Chien-Hao HuangDivision of Hepatology, Department of HepatoGastroenterology, Chang-Gung Memorial Hospital, Linkou Medical Center, TaoYuan, Taiwan.
Wei TengDivision of Hepatology, Department of HepatoGastroenterology, Chang-Gung Memorial Hospital, Linkou Medical Center, TaoYuan, Taiwan.
Wei-Ting ChenDivision of Hepatology, Department of HepatoGastroenterology, Chang-Gung Memorial Hospital, Linkou Medical Center, TaoYuan, Taiwan.
Yi-Cheng ChenSchool of Medicine, College of Medicine, Chang-Gung University, 5, Fu-Xin street, Quain San, TaoYuan, 330, Taiwan.
Chun-Yen LinSchool of Medicine, College of Medicine, Chang-Gung University, 5, Fu-Xin street, Quain San, TaoYuan, 330, Taiwan. chunyenlin@gmail.com.ORCID http://orcid.org/0000-0003-3007-3190
I-Shyan SheenSchool of Medicine, College of Medicine, Chang-Gung University, 5, Fu-Xin street, Quain San, TaoYuan, 330, Taiwan.

Funding

Chang Gung Memorial Hospital, Linkou CMRPG3A1021, CMRPG3A1022, CMRPG3A1023Ministry of Science and Technology, Taiwan 104-2815-C-182A-004-B
6 · The paper itself

Abstract

backgroundChemokines/cytokines play important roles in the pathogenesis of chronic hepatitis C (CHC). However, their clinical characteristics and implications in treatment responses to pegylated interferon plus ribavirin treatment (PegIFN/RBV) have not been fully illustrated yet. In this study, we intended to investigate the possible predictability of serum chemokines/cytokines on the treatment response in Taiwanese of CHC, genotype-1 (GT-1).

methods60 Patients with GT-1 CHC infection who had been treated with PegIFN/RBV were enrolled, including 27 (45%) with sustained virological response (SVR), 11 (18%) with relapse after 48 weeks of treatment and 22 (37%) non-response (NR). Clinical parameters, seven chemokines/cytokines, CCL3, CCL4, CXCL9, CXCL10, CXCL11, IL-10 and IFN-γ, and genotypes of rs12979860, the single nucleotide polymorphisms (SNPs) of interleukin-28B (IL28B) were analyzed for their relationship to treatment response.

resultsBaseline serum levels of CXCL10, CXCL11, CCL3 and CCL4 were significantly higher in NR group while comparing with non-NR group. (CXCL10: p = 0.001; CXCL11: p < 0.001; CCL3: p = 0.006; CCL4: p = 0.005). However, only rs12979860 CC genotype was the independent factors for NR in GT-1 CHC infection (OR, 8.985; p = 0.008). In addition, baseline serum level of CCL4 was found to be the only independent factor for NR in GT-1 CHC patients with favorable IL28B genotype (OR, 1.134; p = 0.039).

conclusionsIL28B genotype is the predictor for NR in GT-1 CHC patients treated with PegIFN/RBV, while baseline serum level of CCL4 is the only predictor for NR in GT-1 CHC patients with favorable IL28B genotype.

Indexed as

Antiviral AgentsChemokinesCytokinesFemaleGenotypeHepacivirusHepatitis C, ChronicHumansInterferon-alphaInterferon alpha-2Interferon LambdaInterferonsInterleukinsMaleMiddle AgedPolyethylene GlycolsAntiviral AgentsChemokinesCytokinesInterferon-alphaInterferon alpha-2Interferon Lambdainterferon-lambda, humanInterferonsInterleukinspeginterferon alfa-2apeginterferon alfa-2bPolyethylene GlycolsRecombinant ProteinsRNA, ViralChemokinesChronic hepatitis CCytokinesGenotype-1Interleukin-28B polymorphismTreatment response

Identifiers

PMID29284412
PMCPMC5747242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.